Grey Matters Health Inc.
GREY.CN
Canadian Securities Exchange0.49
CAD
+0.02
- -
CIK
0001642178
ISIN
CA3978841078
CUSIP
397884107
Return %
Stock
S&P500
1Y
-30.00
19.99
3Y
-77.21
68.07
5Y
-98.13
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christopher J. Moreau
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 601 West Broadway Vancouver BC Canada V5Z 4C2
- IPO Date
- Feb 1, 2016
- CIK
- 0001642178
- Website
- greymattershealth.ca
- Similar Companies
- Business
- Grey Matters Health Inc. is a clinical stage pharmaceutical development company focused on advancing therapies for liver disease, non-alcoholic steatohepatitis, chronic kidney disease, and stroke programs. The company operates in Canada and Australia, advancing a pipeline that includes repirinast for chronic kidney disease and N,N-Dimethyltryptamine for treatment of strokes and traumatic brain injuries, with additional research programs in related hepatology and neurology indications. Founded in 2015, it is headquartered in Frankfurt am Main, Hesse, Germany, and trades on the Canadian Securities Exchange under the GREY ticker. Core products and services include: discovery and preclinical to clinical development of therapeutic drug candidates; formulation and pharmacology studies; regulatory strategy and investor relations support for clinical-stage products; GMP-compliant manufacturing partnerships for translational and early-stage clinical materials; and strategic collaboration management with research institutions and contract development and manufacturing organizations (CDMOs). The company’s primary business activities center on identifying, validating, and advancing drug candidates through early-phase trials, with an emphasis on therapies addressing chronic kidney disease, liver disease, and acute neurological injuries. Latest major changes include: formation of strategic alliances and collaborations with research partners to accelerate pipeline candidates into clinical evaluation; execution of financing activities and potential equity transactions to support continued clinical development; updates to its corporate branding and corporate information under the GREY ticker; and organizational refinements to align operations across Canada and Australia for streamlined trial execution and regulatory submissions. The company also undergoes ongoing exploration of potential acquisitions or partnerships to broaden its development portfolio and strengthen its clinical development capabilities, with a view toward expanding its geographic footprint and capitalizing on emerging opportunities in hepatology and neurology therapeutic spaces. Subsidiary and parent relationships are aligned through a public listing on the CNSX/CSE and related cross-listings, enabling broader access to capital and strategic collaborations. Industry and business segments encompass pharmaceutical development services, translational research, and early-stage clinical development within biotechnology. Target markets include institutional investors, research partners, and potential licensing or collaboration partners seeking early-stage oncology-adjacent and neurology-focused therapeutic candidates, with geographic emphasis on Canada and Australia and academic hospital collaborations. Founding year is 2015, with headquarters in Frankfurt am Main, Germany, and additional corporate activities anchored in Canada and Australia to support clinical-stage drug development programs. The company maintains a network of CDMOs and contract research organizations (CROs) to support its clinical programs and potential future commercialization efforts.